NEWS

DECELL POISED FOR
GROWTH IN 2021

January 11, 2021
 

Late in 2020, DeCell Technologies released a "flourish of announcements – including a unique patent approval – that position the Halifax-area life sciences company for growth in 2021. The company, which makes a natural regenerative scaffolding for wounds, said in November that it had obtained patents for its “prECM decellularization technology” in the U.S., Canada, and five European countries – the U.K., France, Spain, Germany and Italy. What’s interesting about the approval is that the patent covers not just a product or piece of technology but the process used in producing DeCell’s "flagship product DermGEN.

 

Two months earlier, the company unveiled a regional distribution agreement with Impactful Health Solutions of New Jersey and Pharmed Healthcare of Cairo. Under this deal, DermGEN can be sold into eight countries in the Middle East and Northern Africa. These are the latest chapters in an eight-year journey in which Chief Science Officer Paul Gratzer and COO Sean Margueratt have worked to improve the treatment of chronic foot ulcers, which are a common and dangerous ailment suffered by diabetics. Working with partners from around the world, they are trying to give healthcare workers not only better tools for treating this affliction but also enhanced knowledge and best practice.

DECELL TECHNOLOGIES OBTAINS FIRST EVER IN THE WORLD PATENT PROTECTION

November 4th, 2020
 

DeCell Technologies has now obtained patents for it's novel and innovative prECM™ decellularization technology in the U.S., Canada, and five countries in the E.U. (UK, France, Spain, Germany and Italy). These patents include process protection and for the first time ever—composition of matter protection defining the quality of decellularized tissues produced by the prECM™ process. Further, the patents also secure DeCell's novel liquid-based soft tissue sterilization that eliminates the need for using tissue disrupting radiation or energy based sterilization methods.

DECELL SIGNS DEAL
COVERING MIDDLE EAST
AND NORTH AFRICA

September 25th, 2020
 

Impactful Health Solutions Inc. is excited to announce the signing of a regional distribution Agreement with DeCell Technologies & Pharmed Healthcare. This partnership will bring a truly innovative wound healing solution (DermGEN™) into 8 countries in the MENA region. 

DermGEN™ is the most advanced Acellular Dermal Matrix (ADM) product created using the most advanced decellularization process (prECM™). DermGEN™ has been shown to close diabetic foot ulcer (DFU) wounds on an average of 3.3 weeks with only one application. 

We are excited to bring this advanced wound healing solution to the healthcare sector in the MENA region, and ultimately to the patients suffering from DFUs or other chronic wounds.

Pharmed Healthcare Inc. is a fast-growing regional healthcare distributor for innovative pharmaceutical and healthcare companies in the MENA region. 

Impactful Health Solutions Inc. is a sales and marketing agency that works with small and medium-sized companies in the US and Canada to expand their innovative healthcare products into the MENA region.

DECELL STRIKES KEY PARTNERSHIPS

November 9th, 2018

DeCell Technologies Inc. and RegenMed—Ontario’s Premiere Tissue Bank—have signed partnership agreements to manufacture DermGEN™ for both domestic and international sales. RegenMed will both manufacture and distribute DermGEN™ in Canada while also manufacturing DermGEN™ for the International markets. In a separate deal, DeCell has partnered with Impactful Health Solutions (IHS) out of New Jersey, U.S.A., to begin sales of DermGEN™ in markets located in the Middle East. These agreements allow DermGEN™ to enter the healthcare market place so that clinicians can have an advanced, cost effective solution to treat chronic and acute wounds.

DECELL ON THE RADIO

January 28th, 2020
 

Dr. Paul Gratzer (CSO of DeCell) is interviewed by Sheldon MacLeod on the Sheldon MacLeod Show, News 95.7 Halifax on Jan. 28th, 2020 about using DermGEN™ to treat First Nations people with diabetic foot ulcers.

REGENMED ANNOUNCES LAUNCH OF DERMGEN™ IN CANADA IN PARTNERSHIP WITH DECELL TECHNOLOGIES

November 6th, 2019

RegenMed—Ontario’s Premiere Tissue Bank located in Thunder Bay, Ontario— and DeCell Technologies Inc. have launched the sale of DermGEN™ for the Canadian marketplace. RegenMed will both manufacture and distribute DermGEN™ in Canada.

DECELL’S 2015 DISCOVERY AWARD PROFILE

November 19th, 2015

DECELL VOTED BEST PRESENTING COMPANY FOR EARLY STAGE GROWTH

June 17th, 2014

DeCell Technologies Inc. was voted as the Best Presenting Company for Early Stage Growth at the 2014 Atlantic Venture Forum.

A huge thank you to our sponsors, keynote speakers, panelists, presenting companies, investors, industry advisory board, and general delegates for making the 2nd annual Atlantic Venture Forum a tremendous success! We look forward to seeing you again at our 2015 Forum happening on June 16 & 17, 2015! The Atlantic Venture Forum was pleased to host 26 of the hottest early and growth stage companies on the Atlantic coast. We look forward to watching these companies excel and wish them all the best!

 

Congratulations to the winners of the 2014 Atlantic Venture Forum.

DECELL FINALIST IN 2014 DISCOVERY AWARDS

November 20th, 2014

DeCell Technologies was selected as 1 of 3 finalists in the Innovation Category for the 2014 Discovery Awards and has been selected again as a finalist in the Innovation category for the 2015 Discovery Awards.